RxDoctor Payments Data

Moshrik Abd-Alamir, MD

Cardiovascular Disease · Toledo, OHNPI 1386879054

Payments from drug & device makers

$35,483in general payments, 2019–2025

Across 212 payments — averaging $167.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$28K
  • Edwards Lifesciences$2K
  • Abbott$2K
  • Bard Peripheral Vascular, Inc.$640
  • Novartis$562
  • Merck$429
  • plus $2K from 22 others

What the payments were for

  • Grants$25,00070%
  • Travel & lodging$6,19017%
  • Food & beverage$4,13812%
  • Education$1540%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,483 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$78,515
Medicare patients
211
Services billed
623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$51,923
EntrestoSacubitril/Valsartan26$32,245
FarxigaDapagliflozin Propanediol25$23,506
BrilintaTicagrelor16$17,748
XareltoRivaroxaban20$14,435
Repatha SyringeEvolocumab13$7,020
Metoprolol Succinate111$1,518
Nifedipine ErNifedipine34$1,106
ClopidogrelClopidogrel Bisulfate58$821
Carvedilol76$800
Atorvastatin Calcium77$750
Amlodipine Besylate94$576
Isosorbide Mononitrate ErIsosorbide Mononitrate55$527
Nitroglycerin27$399
Chlorthalidone14$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$51,92356 claims
AstraZenecaFarxiga, Brilinta$179$41,25541 claims
NovartisEntresto$562$32,24526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →